Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BPMCNASDAQ:CORTNASDAQ:ROIVNASDAQ:SESN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBPMCBlueprint Medicines$127.96-0.2%$99.05$73.04▼$128.50$8.26B0.841.20 million shs4.71 million shsCORTCorcept Therapeutics$70.06-1.6%$71.49$28.04▼$117.33$7.43B0.191.40 million shs1.01 million shsROIVRoivant Sciences$11.32-1.3%$10.76$8.73▼$13.06$7.70B1.165.58 million shs5.85 million shsSESNSesen Bio$10.50$0.37▼$12.58$2.56B0.831.07 million shs93,330 shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBPMCBlueprint Medicines+0.20%+0.24%+28.98%+43.12%+20.79%CORTCorcept Therapeutics-0.08%+3.14%+0.84%+27.08%+118.08%ROIVRoivant Sciences+1.68%+2.41%+6.60%+7.60%+5.91%SESNSesen Bio0.00%0.00%0.00%0.00%0.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBPMCBlueprint Medicines1.1542 of 5 stars2.22.00.00.02.50.80.6CORTCorcept Therapeutics4.6156 of 5 stars3.51.00.04.22.84.21.9ROIVRoivant Sciences2.4381 of 5 stars3.53.00.00.02.12.50.0SESNSesen BioN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBPMCBlueprint Medicines 2.32Hold$129.351.09% UpsideCORTCorcept Therapeutics 3.00Buy$138.2597.33% UpsideROIVRoivant Sciences 3.00Buy$17.5054.59% UpsideSESNSesen Bio 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest SESN, BPMC, ROIV, and CORT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/5/2025BPMCBlueprint MedicinesMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetEqual Weight ➝ Equal Weight$102.00 ➝ $129.006/5/2025BPMCBlueprint MedicinesUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetNeutral ➝ Neutral$88.00 ➝ $129.006/4/2025BPMCBlueprint MedicinesCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong Sell ➝ Hold$83.00 ➝ $129.006/3/2025BPMCBlueprint MedicinesGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price Target$132.006/3/2025BPMCBlueprint MedicinesGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold6/3/2025BPMCBlueprint MedicinesTD CowenSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold6/3/2025BPMCBlueprint MedicinesCitizens JmpSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold6/3/2025BPMCBlueprint MedicinesJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Outperform ➝ Market Perform6/3/2025BPMCBlueprint MedicinesWolfe ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold6/3/2025BPMCBlueprint MedicinesStephensSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold$150.00 ➝ $135.005/28/2025ROIVRoivant SciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$18.00(Data available from 6/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBPMCBlueprint Medicines$562.12M14.70N/AN/A$4.67 per share27.40CORTCorcept Therapeutics$685.45M10.84$1.03 per share67.96$4.92 per share14.24ROIVRoivant Sciences$29.05M264.87N/AN/A$7.76 per share1.46SESNSesen Bio$40M0.00N/A3.39$0.78 per share0.00Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBPMCBlueprint Medicines-$67.09M-$2.47N/A196.86N/A-13.19%-77.49%-20.84%7/30/2025 (Estimated)CORTCorcept Therapeutics$106.14M$1.1655.6037.87N/A22.35%24.54%20.24%8/4/2025 (Estimated)ROIVRoivant Sciences$4.35B-$0.25N/AN/AN/A-119.54%-14.05%-12.81%8/6/2025 (Estimated)SESNSesen Bio-$19.88M-$0.10N/AN/AN/AN/A6.70%5.41%N/ALatest SESN, BPMC, ROIV, and CORT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/29/2025Q4 2025ROIVRoivant Sciences-$0.16-$0.31-$0.15-$0.29$62.17 million$7.57 million5/5/2025Q1 2025CORTCorcept Therapeutics$0.17$0.17N/A$0.17$177.93 million$157.21 million5/1/2025Q1 2025BPMCBlueprint Medicines-$0.42-$0.74-$0.32$0.01$158.31 million$149.41 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBPMCBlueprint MedicinesN/AN/AN/AN/AN/ACORTCorcept TherapeuticsN/AN/AN/AN/AN/AROIVRoivant SciencesN/AN/AN/AN/AN/ASESNSesen BioN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBPMCBlueprint Medicines1.152.852.80CORTCorcept Therapeutics0.013.703.64ROIVRoivant SciencesN/A37.9137.91SESNSesen BioN/A6.106.10Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBPMCBlueprint MedicinesN/ACORTCorcept Therapeutics93.61%ROIVRoivant Sciences64.76%SESNSesen Bio16.45%Insider OwnershipCompanyInsider OwnershipBPMCBlueprint Medicines4.21%CORTCorcept Therapeutics20.80%ROIVRoivant Sciences7.90%SESNSesen Bio3.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBPMCBlueprint Medicines64064.58 million61.22 millionOptionableCORTCorcept Therapeutics300106.05 million83.30 millionOptionableROIVRoivant Sciences860679.81 million657.18 millionOptionableSESNSesen Bio35203.49 million196.98 millionOptionableSESN, BPMC, ROIV, and CORT HeadlinesRecent News About These CompaniesTrey MewesApril 10, 2024 | startribune.comDevin Haney: biography, record, fights and moreDecember 9, 2023 | espn.comTyson Fury: Biography, record, fights and moreDecember 2, 2023 | espn.comWhy the Tucker Carlson Biography Sales Are So PatheticSeptember 13, 2023 | thedailybeast.comSesen Bio (NASDAQ: SESN)August 4, 2023 | fool.comJames McTeigue Biography & MoviesMay 10, 2023 | tribute.caAfter revisions, Philadelphia-based Carisma Therapeutics poised to close merger with Sesen BioMarch 6, 2023 | bizjournals.comSesen Bio wins shareholder approval for Carisma mergerMarch 2, 2023 | msn.comSesen Bio Stockholders Approve Merger with Carisma TherapeuticsMarch 2, 2023 | finance.yahoo.comSesen Bio Reports Fourth Quarter and Full-Year 2022 Financial ResultsFebruary 28, 2023 | finance.yahoo.comSHAREHOLDER ALERT: Weiss Law Reminds SESN, MLVF, VLON, and SHBI Shareholders About Its Ongoing InvestigationsFebruary 24, 2023 | benzinga.comLeading Independent Proxy Advisory Firm Glass Lewis Joins ISS in Recommending That Sesen Bio Stockholders Vote "FOR" All Proposals to Approve Pending Merger With CarismaFebruary 21, 2023 | finance.yahoo.comBML, One of Sesen Bio's Top Stockholders, Announces Support for Pending Merger with Carisma TherapeuticsFebruary 17, 2023 | stockhouse.comLeading Independent Proxy Advisory Firm ISS Recommends Sesen Bio Stockholders Vote “FOR” All Proposals at March 2 Special MeetingFebruary 16, 2023 | businesswire.comSesen Bio to Host Webcast with Carisma Therapeutics to Discuss Pending MergerFebruary 16, 2023 | finance.yahoo.comSesen Bio reaches deal with investor group, paving way for Carisma mergerFebruary 15, 2023 | endpts.comLatest terms of Sesen Bio and Carisma merger appear to pass musterFebruary 15, 2023 | thepharmaletter.com5 big dividend moves: Group 1 Automotive hikes by 20% | Pro RecapFebruary 15, 2023 | finance.yahoo.comBML, One of Sesen Bio’s Top Stockholders, Announces Support for Pending Merger with Carisma TherapeuticsFebruary 15, 2023 | finance.yahoo.comSesen Bio, Carisma Therapeutics amend merger deal after reaching agreement with investor groupFebruary 14, 2023 | bizjournals.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeSESN, BPMC, ROIV, and CORT Company DescriptionsBlueprint Medicines NASDAQ:BPMC$127.96 -0.25 (-0.19%) Closing price 04:00 PM EasternExtended Trading$128.38 +0.42 (+0.32%) As of 04:29 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders. It is also developing GAVRETO for the treatment of RET fusion-positive non-small cell lung cancer, altered thyroid carcinoma, and medullary thyroid carcinoma; BLU-945 for the treatment of epidermal growth factor receptor driven non-small-cell lung carcinoma (NSCLC); and BLU-451 to treat NSCLC in patients with epidermal growth factor receptor gene (EGFR) exon 20 insertion mutations. In addition, the company is developing BLU-782, for the treatment of fibrodysplasia ossificans progressive; BLU- 222 to treat patients with cyclin E aberrant cancers; and BLU-852 for the treatment of advanced cancers. It has collaboration and license agreements with Clementia Pharmaceuticals, Inc.; Proteovant Therapeutics; CStone Pharmaceuticals; Genentech, Inc.; Hoffmann-La Roche Inc.; and Zai Lab (Shanghai) Co., Ltd. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.Corcept Therapeutics NASDAQ:CORT$70.06 -1.12 (-1.57%) Closing price 04:00 PM EasternExtended Trading$70.08 +0.02 (+0.04%) As of 04:23 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. The company is also developing relacorilant, which is in phase III clinical trial for the treatment of cushing's syndrome; treatment for adrenal cancer and cortisol excess which is in phase 1b clinical trial; treatment for prostate cancer which is in phase II clinical trial; and nab-paclitaxel in combination with relacorilant, which is in phase III clinical trial to treat platinum-resistant ovarian tumors. In addition, it develops dazucorilant, which is in phase II clinical trial for the treatment of amyotrophic lateral sclerosis; miricorilant, which is in phase IIb trial for the treatment of nonalcoholic steatohepatitis; and treatment for antipsychotic induced weight gain that is in phase I trial. The company was incorporated in 1998 and is headquartered in Menlo Park, California.Roivant Sciences NASDAQ:ROIV$11.32 -0.15 (-1.31%) Closing price 04:00 PM EasternExtended Trading$11.30 -0.02 (-0.18%) As of 04:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups. It develops VTAMA, a novel topical for the treatment of psoriasis and atopic dermatitis; batoclimab and IMVT-1402, the fully human monoclonal antibodies targeting the neonatal Fc receptor across various IgG-mediated autoimmune indications; and RVT-3101, an anti-TL1A antibody for ulcerative colitis and Crohn's disease. The company was founded in 2014 and is based in London, the United Kingdom.Sesen Bio NASDAQ:SESNSesen Bio, Inc. engages in designing, engineering, and developing targeted protein therapeutics. It offers Vicineum and Proxinium, which target tumor cell surface antigens that allow for rapid internalization into the targeted cancer cell and also have limited expression on normal cells. The company was founded by Reza Dana, K. Christopher Garcia, Gregory L. Verdine, Casey T. Weaver and K. Dane Wittrup on February 25, 2008 and is headquartered in Cambridge, MA. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Super Micro Computer Stock: 2 Levels Smart Money Is Watching Intel's Price Spikes: Noise, or the First Notes of a Turnaround? IBM Up 10 Days in a Row: What’s Driving the Winning Streak? SoFi Stock’s Next Test: Can It Justify Its Premium Valuation? Ignore the Noise—Samsara Stock Is Still a Strong Buy Fastenal Stock After Split: Poised for 5 More Years of Gains Analysts Love Lovesac, But Investors Should Be Cautious Oracle’s Cloud Boom Is Just Getting Started Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
